Unimed, specializing in empowering the application of artificial intelligence (AI) in brain science diagnosis and treatment, will expand its product and service distribution for a better clinical need with the fresh proceeds.
Unimed (Chinese: 同心智医), the new-generation AI brain science diagnosis and treatment platform today announced the completion of its strategic financing round valued at CNY 100 million (USD 15 million).
This round was led by China Merchants Capital (Chinese: 招商局资本) with participation from Bojia Capital (Chinese: 博佳资本) and Foresight Capital (Chinese: 博见资本).
The funding will be used to accelerate the construction and the commercialization of its new-generation AI-enabled brain science diagnosis and treatment platform.
With 42 intelligence properties and multiple proprietary platforms, Unimed’s products and services have fastly colonized China.
Up to now, Unimed has provided services to more than 500 imaging centers and medical institutions across 26 provinces in China. It has served over 330 thousand patients with more than 3900 medical records.
“Unimed’s products and services are designed and customized to meet both doctors’ and patients’ needs,” Liu Weiqi, the founder of Unimed told EqualOcean at an exclusive interview.
Making precise diagnosis and treatment to better fit each patient’s specific needs is what doctors are aiming for in the clinical operation. To be the doctors’ best helper is how Unimed positions their products. Moreover, Unimed’s unique algorithm combining both casual inference and deep learning will provide more evidence-based solutions to support doctors.
“Meanwhile, we do care our patients’ feelings when being treated. We aim to minimize the injury and pain that patients go through in the medical treatment,” Liu added.
In China, there are around 70 million patients with cerebral aneurysm. Only 0.5% to 1% of them will have cerebral aneurysm rupture. Due to the unpredicted risk and uncertainty, doctors tended to operate on brain aneurysms without further observation in the past.
“Now, with the implementation of Unimed’s services and products, most patients do not need a surgery and can be treated conservatively. In this way, we not only eased patients’ physical burden but also eased their financial burden. More cases like this will also help promote the medical insurance cost control in China in the long term,” Liu said.
Unimed Brain Science is the medical technology R&D platform with a focus on solving the pain points of the application of AI in healthcare such as unexplainable results by traditional deep learning algorithm and poor generalization of models.
Unimed Neosoph is the AI product transformation platform aiming to closely connect Unimed’s products and services with doctors, patients and local hospitals. Some of Neosoph-based products have been issued with National Medical Products Administration (NMPA) certification.
Other companies that employ AI in medical treatment include Tryye Technology (Chinese: 奇誉科技)， Medbot (Chinese: 微创机器人) and Walletek (Chinese: 瓦力泰克).